Pacing-induced AF susceptibility in placebo and atorvastatin-treated WT and NOX2-Tg mice. (A) Percentages of NOX2-Tg and WT mice with inducible AF episodes lasting at least 2 s (n numbers as indicated). (B) The probability of AF (≥2 s) induction per mouse was not different between genotypes (P = 0.83) and there was no effect of ATV (P = 0.89). (C) Maximum AF durations tended to be longer in placebo-fed NOX2-Tg mice (117 s, 25th–75th percentile: 40–381 vs. 68 s, 25th–75th percentile: 32–433 s for placebo-fed WT) and shorter with ATV treatment (P = 0.07; WT, 43 s, 25th–75th percentile: 25–242 s vs. NOX2-Tg, 65 s, 25th–75th percentile: 22–261 s). (D) Cumulative AF duration was significantly lower in mice who received ATV (P = 0.038 vs. placebo), independent of genotype. AF probability and durations were quantified from mice that developed AF lasting at least 2 s (for placebo, n = 19 WT and n = 25 NOX2-Tg mice; for ATV, n = 22 WT and n = 27 NOX2-Tg mice). Categorical data are shown as percentages and P-values were calculated using the Fisher’s exact test. Continuous data are shown as individual data points with means and SDs or medians and IQRs and P-values were calculated by two-way ANOVA with Tukey post hoc analysis. To achieve normality, non-parametric data were log-transformed before statistical analysis.